**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 64212

**Manuscript Type:** MINIREVIEWS

**impact of SARS-CoV-2 on neuropsychiatric disorders**

Robinson-Agramonte MA *et al*. SARS-CoV-2 and neuropsychiatric disorders

Maria de los Angeles Robinson-Agramonte, Carlos Alberto Saraiva Goncalves, Elena Noris-García, Naybí Préndes Rivero, Anna Lisa Brigida, Stephen Schultz, Dario Siniscalco, Ramiro Jorge García

**Maria de los Angeles Robinson-Agramonte,** Neuroimmunology Department, Research Center, International Center for Neurological Restoration, Havana 11300, Cuba

**Carlos-Alberto Gonçalves,** Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Brazil

**Elena Noris-García,** Immunology Department, National Institute of Nephrology, Havana 10600, Cuba

**Naybí Préndes Rivero,**  Department of Mental Health, San Antonio de los Baños Hospital, Havana 38100, Cuba

**Anna Lisa Brigida,** Department of Mental and Physical Health and Preventive Medicine, University of Campania, Naples 80138, Italy

**Stephen Schultz,** Department of Cellular and Integrative Physiology, School of Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, United States

**Dario Siniscalco,** Department of Experimental Medicine, University of Campania, Naples 80138, Italy

**Ramiro Jorge García,** Children Hospital “Juan Manuel Márquez”, Havana 11500, Cuba

**Author contributions:** All authors listed made a substantial, direct and intellectual contribution to the work, and approved it for publication. Robinson-Agramonte MA organized and planned the manuscript; Robinson-Agramonte MA, Rivero NP and García EN wrote the paper; Siniscalco D drafted and revised the manuscript; Saraiva Goncalves CA and García RJ critically revised the manuscript; Brigida AL searched and provided the references, Schultz S edited and corrected the manuscript.

**Corresponding author: Maria de los Angeles Robinson-Agramonte, MD, Professor,** Neuroimmunology Department, Research Center, International Center for Neurological Restoration, Ave 25 # 15805 e/n 158 y 160., Havana 11300, Cuba. neuromary2018@gmail.com

**Received:** February 11, 2021

**Revised:** March 18, 2021

**Accepted:** May 24, 2021

**Published online:** July 19, 2021

**Abstract**

Evolving data show a variable expression of clinical neurological manifestations in patients suffering with coronavirus disease 2019 (COVID-19) from early disease onset. The most frequent symptoms and signs are fatigue, dizziness, impaired consciousness, ageusia, anosmia, radicular pain, and headache, as well as others. Based on the high number of series of cases reported, there is evidence for the implication of the immune system in the pathological mechanism of COVID-19. Although the exact role of the immunological mechanism is not elucidated, two main mechanisms are suggested which implicate the direct effect of severe acute respiratory syndrome coronavirus 2 infection in the central nervous system and neuroinflammation. In the context of neurological manifestations associated with COVID-19, neuropsychiatric disorders show an exacerbation and are described by symptoms and signs such as depression, anxiety, mood alterations, psychosis, post-traumatic stress disorder, delirium, and cognitive impairment, which appear to be common in COVID-19 survivors. A worsened score on psychopathological measures is seen in those with a history of psychiatric comorbidities. We review the neuropsychiatric manifestations associated with COVID-19 and some critical aspects of the innate and adaptive immune system involved in mental health disorders occurring in COVID-19.

**Key Words:** COVID-19; Immunological mechanism; Neuropsychiatric manifestation; Cytokine storm; Adaptive immune response; Innate immune response

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Robinson-Agramonte MA, Gonçalves CA, Noris-García E, Préndes Rivero N, Brigida AL, Schultz S, Siniscalco D, García RJ. impact of SARS-CoV-2 on neuropsychiatric disorders. *World J Psychiatr* 2021; 11(7): 347-354

**URL:** https://www.wjgnet.com/2220-3206/full/v11/i7/347.htm

**DOI:** https://dx.doi.org/10.5498/wjp.v11.i7.347

**Core Tip:** Severe acute respiratory syndrome coronavirus 2 infects the central nervous system and drives neuroinflammation. In coronavirus disease 2019 (COVID-19) patients, neuropsychiatric disorders are showing an exacerbation and are described by symptoms and signs such as depression, anxiety, mood alterations, psychosis, post-traumatic stress disorder, delirium, and cognitive impairments. Some critical aspects of the innate and adaptive immune system are also involved in mental health disorders occurring in COVID-19.

**INTRODUCTION**

The Coronavirus Disease 2019 (COVID-19) pandemic, at the time of this publication, has shown a tendency to a reduction in contagiousness globally; however, the fire has not gone out. Reports of the World Health Organization and Johns Hopkins University confirm as of March 18, 2021 that there have been 121 214 686 cases diagnosed around the world and 2 680 740 deaths as consequence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is accepted that this infection affects the nervous system in various ways as the virus is deeply neurotropic and neuroinvasive[1]. It will be necessary to understand the post-infectious manifestations of COVID-19 to guide long-term management of neurodevelopmental and neuropsychiatric diseases.

Data derived from published clinical papers and case reports indicate that the main clinical manifestations of COVID-19 include anosmia, ageusia, central respiratory failure, stroke, acute inflammatory demyelinating polyneuropathy, toxic metabolic encephalopathy, headache, myalgia, myelitis, ataxia, and others[2,3]. As suggested earlier, in the acute phase, COVID-19 is a potential causal factor of neuropsychiatric manifestations, such as encephalopathy, psychosis, insomnia, and mood changes[4].

The neuropsychiatric manifestations of both viral infection *per se* and secondary to the host neuroinflammatory reaction are attributed to: (1) Microglial activation[5,6]; (2) An imbalance of central neurotransmitters, such as noradrenaline, epinephrine, and serotonin (with potential implication in neuropsychiatric disorders); and (3) A disruption of the blood–brain barrier (BBB) leading to peripheral immune cell transmigration into the central nervous system (CNS)[7]. This manuscript reviews core critical aspects of neuropsychiatric disorders and COVID-19 while focusing on the immunopathology and related clinical symptoms.

**POTENTIAL IMMUNE MECHANISM AND NEUROPSYCHIATRIC SYMPTOMS IN COVID-19**

The neuroinvasive potential of coronavirus has been reported in SARS-CoV-1 patients and experimental animals[6], and it was also speculated to include SARS-CoV-2 in relation to the routes and mechanisms of CoV neurotropism[8,9]. Potential mechanisms of neuropsychiatric manifestations in COVID-19 are discussed from different viewpoints[10-13]; however, we will focus this short review on two main core mechanisms in support of CNS involvement in mental health associated with COVID-19: Direct viral infiltration into the CNS and neuroinflammation with related neuropsychiatric manifestations (Figure 1).

**DIRECT VIRAL INFILTRATION INTO THE CNS**

It is well-known that viral infection takes place by recognition and binding of SARS-CoV-2 virus-host receptor, specifically angiotensin-converting enzyme 2 (ACE-2), which is expressed in multiple tissues within the human body, including the CNS[1]. In the CNS, infection has been identified in glial cells and endothelial cells of blood vessels in the brain. In brain blood vessels, it has been demonstrated that it can induce disruption of the BBB and increase permeability[14-16].

One pathway for CoV invading the CNS is through synaptic routes of nerve cells, which seems to infect CNS retrograde *via* peripheral sensory nerves[17]. On the other hand, the olfactory nerve cells seem to be a feasible route for direct CNS infection, facilitated by the ACE-2 receptor expressed in olfactory epithelial cells[1]. Although this mechanism does not have a full consensus from various research groups, several pieces of evidence confirm that after cell infection by CoVs, death can be caused by autophagy, apoptosis, pyroptosis, or by elimination *via* innate immune cells[17,18] (Figure 1).

**NEUROINFLAMMATION**

It has been found that following SARS-CoV-2 infection, activation of both the innate and adaptive arms of the immune system are induced toward an uncontrolled systemic response with the intervention of a non-specific immune mechanism involving activated macrophages, neutrophils, and natural killer cells, as well as an adaptive immune mechanism with a relevant effector function mediated by dendritic cells and lymphocytes. The adaptive mechanism includes T helper cells (CD4), T cytotoxic cells (CD8) and B cells, which is followed by exaggerated pro-inflammatory cytokine release from these effector cells, such as interleukin (IL)-1b, IL-6, IL-10, IL-12, interferons (IFN)-alpha, IFN-gamma, tumor necrosis factor (TNF)-alpha, transforming growth factor-beta, and chemokines (CCL2, CCL3, CCL5, CXCL8, y/o CXCL10). This begins the so-called "cytokine storm", which is critical for the multi-organ failure leading to high lethality observed in affected patients[12,19-22].

The neuroinflammation caused by SARS-CoV-2, secondary to the cytokine storm and immune cells reactivation, also becomes an additional effect of CoV infection[21]. In this context, several pathways have been discussed regarding the strong immune response in humans secondary to SARS-CoV-2 infection[22]. A marked reduction in absolute count of T cells, monocytes, eosinophils, and basophils has been found during this infection, with a main impact on the absolute decrease of T cells, memory T helper and regulatory cells[23,24].

Besides the explosive cytokine release syndrome and the macrophage activation syndrome co-existing in SARS-CoV-2 infection and affecting the CNS, there is also a strong increase in pro-inflammatory cytokines, such as IL-6, IL-2, IL-17, granulocyte-colony stimulating factor and TNF[24]. Inflammatory conditions can also induce the increase of IL-1, IL-6 and TNF soluble mediators that might facilitate major BBB permeability[25], as they have been responsible for neurological manifestations such as encephalitis, CNS demyelination and neuropsychiatric disorders[26].

Even in the absence of SARS-CoV-2 CNS infiltration, a transmigration of peripheral cytokines derived from the systemic host antiviral response may also take place to induce neuropsychiatric symptoms by the neuro-inflammatory response and BBB disruption. This may be caused by the peripheral effector immune cells migrating into the CNS, as well as local impairment of the neurotransmission system[27,28]. High levels of neurotransmitters, mainly noradrenaline, epinephrine, and serotonin, have been associated with psychological manifestations, such as depression, anxiety, and post-traumatic stress disorder[20].

It seems possible that the hypothesis of cytokine storm being associated with psychiatric manifestation induction is an indirect consequence of the hyperinflammation. Previous studies regarding pandemics caused by respiratory viruses suggest that diverse occurrence of neuropsychiatric symptoms can take place during or after the acute infection, which may be underlined by the presence of persistent cognitive deficits.

In the COVID-19 acute phase, besides the psychosocial stressor factors, it has been argued that the infection underlying the pathophysiology of neuropsychiatric manifestations, such as encephalopathy, psychosis, insomnia, and mood changes, post-traumatic stress disorder, panic attacks, and anxiety, mostly seen in health care workers and survivors of SARS-CoV infection, have been mainly attributed to viral infection *per se* and secondary to the host immune response. In this way, direct viral infiltration of the CNS can trigger an inflammatory reaction at the brain level leading to local microglial activation, which in turn induces demyelinating processes that are one of the primary causes of encephalopathy. In the absence of direct viral infiltration, a peripheral cytokine storm causing an imbalance of neurotransmitters within the CNS has been implicated in neuropsychiatric manifestations. This cytokine storm induces a neuroinflammatory response causing disruption of the BBB, leading to peripheral immune cell transmigration into the brain and, in turn, causes imbalances in neurotransmission.

It continues to be a challenge for researchers to elucidate the real core mechanisms of COVID-19 associated neuropsychiatric complications due to general findings caused by SARS-CoV-2 infection. This may be difficult to distinguish from the encephalopathy arising from systemic infection without affecting brain tissue[29]. Evidence such as the increase in IL-6 has been linked to high mortality in patients with COVID-19[19], similar to the increase in this cytokine observed in other neuropsychiatric disorders such as schizophrenia and depression[19].

Other arguments underlining the immunological mechanism identify that peripheral myeloid cells are also infected by CoV[5], which can be recruited to transmigrate to the CNS under an increased BBB permeability. Virus-infected monocytes in the CNS can promote microglial activation as well as induce neuropsychiatric symptoms[5,27,28]. The role of microglial activation in schizophrenia and autism is well known[30,31,32]. Other mechanisms implicating mental disease in COVID-19 are the close inter-relation between the systemic compartment and the brain[7] (Figure 1).

**NEUROPSYCHIATRIC FINDINGS IN THE COVID-19 PANDEMIC**

Since the initial phase of the COVID-19 pandemic, a large number of studies have shown the clinical symptoms and signs of the infection. These principally include fever, cough, sore throat, dyspnea, nausea, diarrhea, and fatigue[27,33]. However, numerous reports also reveal an accumulation of frequent neurological symptoms in COVID-19 positive patients, such as dizziness, ageusia, fatigue, headache, impaired consciousness, and anosmia[34-36].

Parallel to the neurological events, evidence is growing for neuropsychiatric disorders that are also reported as secondary complications of SARS-CoV-2 infection[37], which will be made clear in the few years. In this context, an exacerbation of mental health disorders has been described in COVID-19 that include delirium, cognitive impairment, mood alterations, and psychosis[38-40]. Delirium occurs in 90% of COVID-19 cases, while cognitive disorder is also considered a direct consequence of CNS infection by SARS-CoV-2[39]. Anxiety, depression, post-traumatic stress disorder, insomnia, and obsessive-compulsive symptomatology, mainly in females, appear to be quite common in COVID-19 survivors and coworkers with worsened scores on psychopathological measures in those with a history of psychiatric comorbidities. In addition, hypoxemia, a frequent clinical finding in COVID-19, can also produce mental health impairment[38]. Thus, a consequence of acute respiratory syndrome and associated relative hypoxia also shows worsening of attention, executive function, and verbal memory[41].

An exaggerated immune response, under a dysregulated cytokine network, occurring during the COVID-19 pandemic would also drive symptoms of visceral stress with an impact on mental health[38,42]. In this line of thinking, authors have defined a relationship between COVID-19 disease severity, somatic and psychiatric symptoms, and cytokine levels in patients positive for SARS-CoV-2 infection. There is also some evidence that patients with comorbidities and immunosuppression are more susceptible to developing psychiatric disorders, such as cognitive impairment, anxiety, and depression[43,44].

Considering the trajectory of the occurrence of COVID-19 around the world, from its beginnings in China in December 2019, it is clear that not only patients but also their family and the normal population are victims of the psychosocial impacts derived from this pandemic[42,45]. From this viewpoint, it is clearly necessary to investigate the behavioral aspects of this disease, either in the short- or long-term, to identify a more valuable strategy to control the transmission by carriers and assess the impact of COVID-19, not only in affected patients, but also in the general population. We are proposing a diagram regarding the impact of the immunological mechanism involved in SARS-CoV-2 infection by the occurrence of neuropsychiatric manifestation as a tool of acknowledgment of the way the disease progresses which could allow better management of the disease and prevention of the consequences in the short- or long-term.

The long-term neuropsychiatric consequences of SARS-CoV-2 infection have been demonstrated in a fraction of cases; however, they appear to be significant for the future due to the global burden of COVID-19. In this context, to understand the evolution and specificity of neuropsychiatric outcomes stemming from SARS-CoV-2 infection and to elucidate the pathogenic mechanisms involved in these events should be useful in targeting critical interventions for the prevention of mental disorders derived from COVID-19. Nevertheless, the work of psychologists and psychiatrists concentrated on handling the psyche at clinics and paraclinics looking for more effective evidence of recovery from the potential neurological consequences will not be enough. It will be necessary to develop programs and strategies to achieve a more humanist medical approach to promote the resilience of the individuals affected as well as their parents to avoid the long-term occurrence of mental disorders due to the lost connection between the body and the soul. This is the neurobiological substrate in the development of neuropsychiatric disorders as a consequence of COVID-19. Finally, an earlier understanding of the characteristics of neuropsychiatric outcomes stemming from SARS-CoV-2 infection and their pathogenic mechanisms will be necessary as an intervention target to avoid the sub-acute or chronic neuropsychiatric consequences of SARS-CoV-2 infection.

**CONCLUSION**

According to the numerous articles published since the beginning of the COVID-19 pandemic, it could be surmised that the accumulated knowledge would be enough to understand many of the events occurring in this illness. However, there is not enough data to understand the long-term consequences of this disease. The neuropsychiatric dysfunctions as part of the group of disorders unknown in the evolutionary context of COVID-19 could also be the result of an exaggerated host response against SARS-CoV-2 infection. The impact on the permeability of the BBB which facilitates the migration of immune cells to the CNS and their deleterious effect on neural function, followed by deregulation of the cytokine network that affects mental health, are manifested more frequently by anxiety, cognitive impairment and major depressive disorder. More studies will continue to be necessary to address this topic.

**REFERENCES**

1 **Arbour N**, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. *J Virol* 2000; **74**: 8913-8921 [PMID: 10982334 DOI: 10.1128/jvi.74.19.8913-8921.2000]

2 **Chen T**, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020; **368**: m1091 [PMID: 32217556 DOI: 10.1136/bmj.m1091]

3 **Li YC**, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol* 2020; **92**: 552-555 [PMID: 32104915 DOI: 10.1002/jmv.25728]

4 **Troyer EA**, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. *Brain Behav Immun* 2020; **87**: 34-39 [PMID: 32298803 DOI: 10.1016/j.bbi.2020.04.027]

5 **Wohleb ES**, Delpech JC. Dynamic cross-talk between microglia and peripheral monocytes underlies stress-induced neuroinflammation and behavioral consequences. *Prog Neuropsychopharmacol Biol Psychiatry* 2017; **79**: 40-48 [PMID: 27154755 DOI: 10.1016/j.pnpbp.2016.04.013]

6 **Desforges M**, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, Talbot PJ. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? *Viruses* 2019; **12**: 14 [PMID: 31861926 DOI: 10.3390/v12010014]

7 **Dantzer R**. Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. *Physiol Rev* 2018; **98**: 477-504 [PMID: 29351513 DOI: 10.1152/physrev.00039.2016]

8 **Vavougios GD**. Host proteases as determinants of coronaviral neurotropism and virulence. *Brain Behav Immun* 2020; **87**: 27 [PMID: 32272221 DOI: 10.1016/j.bbi.2020.04.010]

9 **Wu Y**, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun* 2020; **87**: 18-22 [PMID: 32240762 DOI: 10.1016/j.bbi.2020.03.031]

10 **Gómez-Rial J**, Currás-Tuala MJ, Rivero-Calle I, Gómez-Carballa A, Cebey-López M, Rodríguez-Tenreiro C, Dacosta-Urbieta A, Rivero-Velasco C, Rodríguez-Núñez N, Trastoy-Pena R, Rodríguez-García J, Salas A, Martinón-Torres F. Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology. *Front Immunol* 2020; **11**: 560381 [PMID: 33072099 DOI: 10.3389/fimmu.2020.560381]

11 **Xiang YT**, Zhao YJ, Liu ZH, Li XH, Zhao N, Cheung T, Ng CH. The COVID-19 outbreak and psychiatric hospitals in China: managing challenges through mental health service reform. *Int J Biol Sci* 2020; **16**: 1741-1744 [PMID: 32226293 DOI: 10.7150/ijbs.45072]

12 **Chen Y**, Wang J, Liu C, Su L, Zhang D, Fan J, Yang Y, Xiao M, Xie J, Xu Y, Li Y, Zhang S. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. *Mol Med* 2020; **26**: 97 [PMID: 33121429 DOI: 10.1186/s10020-020-00230-x]

13 **Russell CD**, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020; **395**: 473-475 [PMID: 32043983 DOI: 10.1016/S0140-6736(20)30317-2]

14 **Baig AM**, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. *ACS Chem Neurosci* 2020; **11**: 995-998 [PMID: 32167747 DOI: 10.1021/acschemneuro.0c00122]

15 **Xu H**, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci* 2020; **12**: 8 [PMID: 32094336 DOI: 10.1038/s41368-020-0074-x]

16 **Zhang H**, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med* 2020; **46**: 586-590 [PMID: 32125455 DOI: 10.1007/s00134-020-05985-9]

17 **Hwang CS**. Olfactory neuropathy in severe acute respiratory syndrome: report of A case. *Acta Neurol Taiwan* 2006; **15**: 26-28 [PMID: 16599281]

18 **Varga Z**, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020; **395**: 1417-1418 [PMID: 32325026 DOI: 10.1016/S0140-6736(20)30937-5]

19 **Zhang C**, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents* 2020; **55**: 105954 [PMID: 32234467 DOI: 10.1016/j.ijantimicag.2020.105954]

20 **Ragab D**, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. *Front Immunol* 2020; **11**: 1446 [PMID: 32612617 DOI: 10.3389/fimmu.2020.01446]

21 **Accinelli RA**, Zhang Xu CM, Ju Wang JD, Yachachin-Chávez JM, Cáceres-Pizarro JA, Tafur-Bances KB, Flores-Tejada RG, Paiva-Andrade ADC. COVID-19: la pandemia por el nuevo virus SARS-CoV-2. *Rev Peru Med Exp Salud Publica* 2020; **37**: 302-311 [PMID: 32876222 DOI: 10.17843/rpmesp.2020.372.5411]

22 **Bae YS**, Shin EC, Bae YS, Van Eden W. Editorial: Stress and Immunity. *Front Immunol* 2019; **10**: 245 [PMID: 30837994 DOI: 10.3389/fimmu.2019.00245]

23 **Lagunas-Rangel FA**. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *J Med Virol* 2020; **92**: 1733-1734 [PMID: 32242950 DOI: 10.1002/jmv.25819]

24 **Qin C**, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 2020; **71**: 762-768 [PMID: 32161940 DOI: 10.1093/cid/ciaa248]

25 **Netland J**, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. *J Virol* 2008; **82**: 7264-7275 [PMID: 18495771 DOI: 10.1128/JVI.00737-08]

26 **Laing AG**, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, Muñoz-Ruiz M, McKenzie DR, Hayday TS, Francos-Quijorna I, Kamdar S, Joseph M, Davies D, Davis R, Jennings A, Zlatareva I, Vantourout P, Wu Y, Sofra V, Cano F, Greco M, Theodoridis E, Freedman JD, Gee S, Chan JNE, Ryan S, Bugallo-Blanco E, Peterson P, Kisand K, Haljasmägi L, Chadli L, Moingeon P, Martinez L, Merrick B, Bisnauthsing K, Brooks K, Ibrahim MAA, Mason J, Lopez Gomez F, Babalola K, Abdul-Jawad S, Cason J, Mant C, Seow J, Graham C, Doores KJ, Di Rosa F, Edgeworth J, Shankar-Hari M, Hayday AC. A dynamic COVID-19 immune signature includes associations with poor prognosis. *Nat Med* 2020; **26**: 1623-1635 [PMID: 32807934 DOI: 10.1038/s41591-020-1038-6]

27 **Pereira A**. Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic. *Front Neurol* 2020; **11**: 308 [PMID: 32362868 DOI: 10.3389/fneur.2020.00308]

28 **Wohleb ES**, McKim DB, Sheridan JF, Godbout JP. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior. *Front Neurosci* 2014; **8**: 447 [PMID: 25653581 DOI: 10.3389/fnins.2014.00447]

29 **Inchausti F**, MacBeth A, Hasson-Ohayon I, Dimaggio G. Psychological Intervention and COVID-19: What We Know So Far and What We Can Do. *J Contemp Psychother* 2020: 1-8 [PMID: 32836375 DOI: 10.1007/s10879-020-09460-w]

30 **Robinson-Agramonte MA,** González Fraguela ME, Bergado Rosado ME. Autism, Developmentand Neural Plasticity. Robinson Agramonte MA, editor. Translational Approaches to Autism Spectrum Disorder. Heidelberg: Springer, 2015: 119-135 [DOI: 10.1007/978-3-319-16321-5\_7]

31 **Kazlauskas N,** Robinson Agramonte MA, Mara Depino A. Neuroinflammation in Animal Models of Autism. Robinson Agramonte MA, editor. Translational Approaches to Autism Spectrum Disorder. Heidelberg: Springer, 2015: 137-153 [DOI: 10.1007/978-3-319-16321-5\_8]

32 **Amaicha Mara Depino A,** Robinson Agramonte MA. Understanding on Neuroimmunology in Autism Spectrum Disorder. Robinson Agramonte MA, editor. Translational Approaches toAutism Spectrum Disorder. Heidelberg: Springer, 2015: 155-180 [DOI: 10.1007/978-3-319-16321-5\_9]

33 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

34 **Lee SM**, Kang WS, Cho AR, Kim T, Park JK. Psychological impact of the 2015 MERS outbreak on hospital workers and quarantined hemodialysis patients. *Compr Psychiatry* 2018; **87**: 123-127 [PMID: 30343247 DOI: 10.1016/j.comppsych.2018.10.003]

35 **Liu K**, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC, Liu HG. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)* 2020; **133**: 1025-1031 [PMID: 32044814 DOI: 10.1097/CM9.0000000000000744]

36 **Vaira LA**, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common Findings in COVID-19 Patients. *Laryngoscope* 2020; **130**: 1787 [PMID: 32237238 DOI: 10.1002/lary.28692]

37 **Bao Y**, Sun Y, Meng S, Shi J, Lu L. 2019-nCoV epidemic: address mental health care to empower society. *Lancet* 2020; **395**: e37-e38 [PMID: 32043982 DOI: 10.1016/S0140-6736(20)30309-3]

38 **Carvalho PMM**, Moreira MM, de Oliveira MNA, Landim JMM, Neto MLR. The psychiatric impact of the novel coronavirus outbreak. *Psychiatry Res* 2020; **286**: 112902 [PMID: 32146248 DOI: 10.1016/j.psychres.2020.112902]

39 **Goularte JF**, Serafim SD, Colombo R, Hogg B, Caldieraro MA, Rosa AR. COVID-19 and mental health in Brazil: Psychiatric symptoms in the general population. *J Psychiatr Res* 2021; **132**: 32-37 [PMID: 33038563 DOI: 10.1016/j.jpsychires.2020.09.021]

40 **Mazza MG**, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P; COVID-19 BioB Outpatient Clinic Study group, Benedetti F. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. *Brain Behav Immun* 2020; **89**: 594-600 [PMID: 32738287 DOI: 10.1016/j.bbi.2020.07.037]

41 **Ardila A**, Lahiri D. Executive dysfunction in COVID-19 patients. *Diabetes Metab Syndr* 2020; **14**: 1377-1378 [PMID: 32755837 DOI: 10.1016/j.dsx.2020.07.032]

42 **Noris-García E,** Robinson-Agramonte MA. Psycho-neuro-immuno-endocrinology and COVID-19. *Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta* 2021; **46**

43 **Klok FA**, Boon GJAM, Barco S, Endres M, Geelhoed JJM, Knauss S, Rezek SA, Spruit MA, Vehreschild J, Siegerink B. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. *Eur Respir J* 2020; **56**: 2001494 [PMID: 32398306 DOI: 10.1183/13993003.01494-2020]

44 **Mehta P**, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033-1034 [PMID: 32192578 DOI: 10.1016/S0140-6736(20)30628-0]

45 **Zhu N**, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; **382**: 727-733 [PMID: 31978945 DOI: 10.1056/NEJMoa2001017]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 11, 2021

**First decision:** March 16, 2021

**Article in press:** May 24, 2021

**Specialty type:** Psychiatry

**Country/Territory of origin:** Cuba

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Morenikeji OB **S-Editor:** Liu M **L-Editor:** Webster JR **P-Editor:** Li JH

**Figure Legends**



**Figure 1 Immunological mechanisms of neuropsychiatric manifestations derived from severe acute respiratory syndrome coronavirus 2 infection.** COVID-19: Coronavirus disease 2019; CNS: Central nervous system; NPM: Neuropsychiatric manifestation; Mφ: Macrophages; BBB: Blood-brain barrier; GMCSF: Granulocyte-colony stimulating factor; IL: Interleukin; TNF: Tumor necrosis factor.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**